...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Not adding up!

  "Does anybody really think that because RVX hopes for a good Covid trial, Newsoara would pay more for a license for Zenith's ZEN-3694?"

"Anyhow, I don't see a problem with today's news."

 

not arguing was just speaking to the "Different company.How is this relevant" in general terms.

"No one even knows what the milesone and royalty payments will be but are critical"

as usual with commuication - always & i mean always lacking in any detail & leaving more questions than answers.

Your cool with it anyway, i mean youve stated your not expecting much SP wise till 24-26 or 2027 so your expectations are far lower than mine. If i thought this was dead money for anohter 3-5 years or more I'd have to ask myself why i even stayed this long. Different strokes for different folks i guess. 

 

 

Share
New Message
Please login to post a reply